Camden National Bank lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,465 shares of the company’s stock after selling 25 shares during the period. Camden National Bank’s holdings in Eli Lilly and were worth $368,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Heritage Trust Co bought a new position in shares of Eli Lilly and during the 1st quarter valued at about $135,000. Point72 Asia Hong Kong Ltd boosted its holdings in shares of Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new position in shares of Eli Lilly and during the 2nd quarter valued at about $148,000. Cornerstone Advisors Inc. boosted its holdings in shares of Eli Lilly and by 18.4% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after purchasing an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its holdings in shares of Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after purchasing an additional 176 shares during the last quarter. 75.72% of the stock is owned by institutional investors and hedge funds.
Several research firms have commented on LLY. Barclays PLC increased their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a report on Thursday, July 27th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $96.00 price target (up previously from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $88.57.
Eli Lilly and Company (NYSE:LLY) opened at 86.43 on Friday. The stock’s 50 day moving average is $83.21 and its 200-day moving average is $82.21. The stock has a market capitalization of $91.18 billion, a price-to-earnings ratio of 37.40 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period in the prior year, the business posted $0.86 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/10/13/camden-national-bank-reduces-holdings-in-eli-lilly-and-company-lly.html.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.